Kiniksa Pharmaceuticals Reports Preliminary Q4 And FY2024 Arcalyst Net Product Revenue Of $121.9M And $416.4M, Respectively
- As of the end of the fourth quarter of 2024, approximately 13% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.
- Since launch, more than 2,850 prescribers have written ARCALYST prescriptions for recurrent pericarditis.
- As of the end of the fourth quarter of 2024, average total duration of ARCALYST therapy in recurrent pericarditis was approximately 27 months.
Corporate Update - As of December 31, 2024, Kiniksa had $243.6 million of cash, cash equivalents, and short-term investments (unaudited).
- Kiniksa expects to remain cash flow positive on an annual basis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。